HSBC analyst, Steve McGarry, reiterated a Buy rating on shares of GlaxoSmithKline (NYSE: GSK) while raising the price target to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE